Valneva reports more data on Covid-19 vaccine; ClinChoice buys a CRO
Valneva presented updates on its Covid-19 vaccine, the first to get the full marketing green light in Europe, but the French biotech stopped manufacturing of it last year because of reduced order volume in the EU.
The company said it has extended the vaccine’s shelf life by three months, from 18 to 21 months. It also said the European Medicines Agency’s committee gave a positive opinion for using the vaccine, VLA2001, as a booster dose in adults 18 to 50 years old.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters